Genetic variants of LDLR and PCSK9 associated with variations in response to antihypercholesterolemic effects of Armolipid Plus with berberine

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  De Castro Orós, Isabel ^a   Solà, Rosa ^c   Valls, Rosa María ^b   Brea, Angel ^c   Mozas, Pilar ^a   Puzo, Jose ^d   Pocoví, Miguel ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^c HOSPITAL SAN PEDRO   (Spain)

^d HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ASTHAXANTINE; BERBERINE; CYTOSINE; FOLIC ACID; GUANINE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN RECEPTOR; NUTRACEUTICAL; PLACEBO; POLICOSANOL; UBIDECARENONE; UNCLASSIFIED DRUG; XUEZHIKANG; ASTAXANTHIN; FATTY ALCOHOL; LDLR PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9; SERINE PROTEINASE; XANTHOPHYLL;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; AGE; ANTIHYPERCHOLESTEROLEMIC EFFECT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GENDER; GENE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HYPERCHOLESTEROLEMIA; LDLR GENE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PCSK9 GENE; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; AGED; ALLELE; FEMALE; GENETICS; HETEROZYGOTE; MALE; MIDDLE AGED; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL;

ADULT; AGED; ALLELES; BERBERINE; CHOLESTEROL, LDL; FATTY ALCOHOLS; FEMALE; HETEROZYGOTE; HUMANS; HYPERCHOLESTEROLEMIA; LINEAR MODELS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASES; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; XANTHOPHYLLS;

EID: 84962159229     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150785     Document Type: Article

References (29)

1. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374. PMID: 6361300
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389. PMID: 7968073
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009. PMID: 8801446
4. Group HPSC. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22. PMID: 12114036
5. Lee IT, Lee WJ, Tsai CM, Su IJ, Yen HT, Sheu WH. Combined extractives of red yeast rice, bitter gourd, chlorella, soy protein, and licorice improve total cholesterol, low-density lipoprotein cholesterol, and triglyceride in subjects with metabolic syndrome. Nutr Res. 2012;32:85-92. doi: 10.1016/j.nutres. 2011.12.011 PMID: 22348456
6. Tiwari A, Bansal V, Chugh A, Mookhtiar K. Statins and myotoxicity: a therapeutic limitation. Expert Opin Drug Saf. 2006;5:651-666. PMID: 16907655
7. Sirtori CR, Mombelli G, Triolo M, Laaksonen R. Clinical response to statins: mechanism (s) of variable activity and adverse effects. Ann Med. 2012;44:419-432. doi: 10.3109/07853890.2011.582135 PMID: 21623698
8. Guyton JR, Bays HE, Grundy SM, Jacobson TA, The National Lipid Association Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol. 2014;8:S72-S81. doi: 10.1016/j.jacl.2014.03.002 PMID: 24793444
9. Affuso F, Mercurio V, Ruvolo A, Pirozzi C, Micillo F, Carlomagno G, et al. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol. 2012;4:77-83. doi: 10.4330/wjc.v4.i3.77 PMID: 22451856
10. Pisciotta L, Bellocchio A, Bertolini S. Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. Lipids Health Dis. 2012;11:123. doi: 10.1186/1476-511X-11-123 PMID: 22998978
11. Izzo R, de Simone G, Giudice R, Chinali M, Trimarco V, De Luca N, et al. Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham Risk Score in individuals with dyslipidemia. J Hypertens. 2010;28:1482-1487. doi: 10.1097/HJH.0b013e3283395208 PMID: 20498621
12. Trimarco B, Benvenuti C, Rozza F, Cimmino CS, Giudice R, Crispo S. Clinical evidence of efficacy of red yeast rice and berberine in a large controlled study versus diet. Med J Nutrition Metab. 2011;4:133-139. PMID: 21909461
13. Solà R, Valls RM, Puzo J, Calabuig JR, Brea A, Pedret A, et al. Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial. PLoS One. 2014;9:e101978. doi: 10.1371/journal.pone. 0101978 PMID: 25084280
14. Liu J, Zhang J, Shi J, Grimsgaard S, Alraek T, Fønnebø V. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med. 2006;23:1-4.
15. Menéndez R, Amor AM, Rodeiro I, González RM, González PC, Alfonso JL, et al. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch Med Res. 2001;32:8-12. PMID: 11282173
16. Singh DK, Li L, Porter TD. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. J Pharmacol Exp Ther. 2006;318:1020-1026. PMID: 16714400
17. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10:1344-1351. PMID: 15531889
18. Cameron J, Ranheim T, Kulseth MA, Leren TP, Berge KE. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis. 2008;201:266-273. doi: 10.1016/j.atherosclerosis.2008.02.004 PMID: 18355829
19. Li H, Dong B, Park SW, Lee HS, Chen W, Liu J. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem. 2009;284:28885-28895. doi: 10.1074/jbc. M109.052407 PMID: 19687008
20. De Castro-Orós I, Pampín S, Bolado-Carrancio A, De Cubas A, Palacios L, Plana N, et al. Functional analysis of LDLR promoter and 5' UTR mutations in subjects with clinical diagnosis of familial hypercholesterolemia. Hum Mutat. 2011;32:868-872. doi: 10.1002/humu.21520 PMID: 21538688
21. Jacobs DR, Anderson JT, Hannan P, Keys A, Blackburn H. Variability in individual serum cholesterol response to change in diet. Arteriosclerosis. 1983;3:349-356. PMID: 6882289
22. Beynen AC, Katan MB. Reproducibility of the variations between humans in the response of serum cholesterol to cessation of egg consumption. Atherosclerosis. 1985;57:19-31. PMID: 3907645
23. Beynen AC, Katan MB, Van Zutphen LF. Hypo- and hyperresponders: individual differences in the response of serum cholesterol concentration to changes in diet. Adv Lipid Res. 1987;22:115-171. PMID: 3328488
24. Katan MB, Beynen AC, de Vries JH, Nobels A. Existence of consistent hypo- and hyperresponders to dietary cholesterol in man. Am J Epidemiol. 1986;123:221-234. PMID: 3946372
25. Gerards MC, Terlou RJ, Yu H, Koks CH, Gerdes VE. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain-A systematic review and meta-analysis. Atherosclerosis. 2015;240:415-423. doi: 10.1016/j.atherosclerosis.2015.04.004 PMID: 25897793
26. Wilson GM, Vasa MZ, Deeley RG. Stabilization and cytoskeletal-association of LDL receptor mRNA are mediated by distinct domains in its 3' untranslated region. J Lipid Res. 1998;39:1025-1032. PMID: 9610769
27. Chen W, Wang S, Ma Y, Zhou Y, Liu H, Strnad P, et al. Analysis of polymorphisms in the 3' untranslated region of the LDL receptor gene and their effect on plasma cholesterol levels and drug response. Int J Mol Med. 2008;21:345-353. PMID: 18288382
28. Singh AB, Li H, Kan CF, Dong B, Nicolls MR, Liu J. The critical role of mRNA destabilizing protein heterogeneous nuclear ribonucleoprotein d in 3' untranslated region-mediated decay of low-density lipoprotein receptor mRNA in liver tissue. Arterioscler Thromb Vasc Biol. 2014;34:8-16. doi: 10.1161/ATVBAHA.112.301131 PMID: 24158514
29. Dong B, Li H, Singh AB, Cao A, Liu J. Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway. J Biol Chem. 2015;290:4047-4058. doi: 10.1074/jbc. M114.597229 PMID: 25540198